1. PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA. (June 2017) Authors: Coleman, M.; Andorsky, D.J.; Yacoub, A.; Melear, J.M.; Kolibaba, K.S.; Brooks, H.D.; Bitran, J.D.; Fanning, S.R.; Lansigan, F.; Ricker, J.L.; Foon, K.A.; Llorente, M.; Li, J.; Sharman, J.P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES. (12th June 2019) Authors: Molina, A.; Shah, N.; Krishnan, A.Y.; Shah, N.D.; Burke, J.M.; Melear, J.M.; Spira, A.I.; Popplewell, L.L.; Andreadis, C.B.; Chhabra, S.; Sharman, J.P.; Kaufman, J.L.; Cohen, J.B.; Niesvizky, R.; Martin, T.G.; DiLea, C.; Kuriakose, J.; Matheny, S.L.; Leonard, J.P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 324 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗